文献速递骨质疏松与代谢性骨病

骨化二醇纠正维生素D状态:每日与每周给药方案的药代动力学特征、安全性及对骨与矿物质代谢的生化效应

Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.
PubMed 文献 · Osteoporos Int · 2017-08-16

研究纳入87名55岁及以上、血清25(OH)D不足的社区绝经后女性,随机接受骨化二醇20 μg/日、40 μg/日或125 μg/周治疗3个月。三种方案均使25(OH)D显著且迅速升高并稳定在30 ng/ml阈值以上,对继发性甲状旁腺功能亢进控制效果相当,钙磷代谢及骨转换标志物无显著变化。

要点

  • 骨化二醇每日20 μg、40 μg或每周125 μg治疗3个月均能有效提升血清25(OH)D水平。
  • 三种剂量方案对控制继发性甲状旁腺功能亢进效果相当,且钙磷代谢与骨转换标志物无显著变化。
  • 研究结论认为骨化二醇补充有效且安全,但需进一步研究以跌倒为主要结局。

核心结论

  • 骨化二醇不同每日或每周剂量用于治疗绝经后女性维生素D不足或缺乏时,对矿物质代谢核心参数具有短期和中期疗效及安全性。
  • 需进一步研究以评估骨化二醇补充对跌倒这一主要结局的影响。

研究设计与样本

  • ADDI-D研究为随机对照药代动力学研究,共纳入87名55岁及以上、社区居住的白人绝经后女性,血清25(OH)D水平<30 ng/ml且平均25(OH)D低于20 ng/ml(均值16.5 ± 7.5 ng/ml)。
  • 受试者随机接受骨化二醇20 μg/日、40 μg/日或125 μg/周治疗3个月。

主要发现

  • 所有三组血清25(OH)D值均显著且迅速升高,治疗14天后稳定在30 ng/ml阈值以上并保持在安全区间内,相近的每日与每周剂量方案疗效相似。
  • 不同剂量对控制继发性甲状旁腺功能亢进同样有效。
  • 任何治疗均未观察到钙磷代谢及骨转换标志物的显著变化。

关键数值与推荐

  • 主要终点为达到的血清25(OH)D水平以评估疗效。
  • 次要终点包括血清钙、甲状旁腺激素、磷酸盐、FGF23、尿钙及骨转换标志物以评估安全性。

局限性

  • 需进一步研究以评估骨化二醇补充对跌倒这一主要结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Calcidiol can be employed to correct vitamin D deficiency. MAIN RESULTS: Calcidiol administered at daily and weekly regimens over a period of 3 months was able to successfully raise 25-hydroxyvitamin D levels without altering other markers related to bone and mineral metabolism. SIGNIFICANCE: Calcidiol supplementation is effective and safe. INTRODUCTION: The correction of vitamin D status is necessary to maintain an optimal mineral and skeletal homeostasis. Despite cholecalciferol (vitamin D3) is the most commonly used drug for vitamin D supplementation, the more hydrophilic compound calcidiol (25-hydroxyvitamin D3) can be employed at daily, weekly, and monthly regimens to reach in the short term the target levels of serum 25-hydroxyvitamin D [25(OH)D]. In the administration of different doses of calcidiol pharmacokinetic study (ADDI-D study), the efficacy and safety of daily and weekly dosages of calcidiol were tested. METHODS: A total of 87 Caucasian, community-dwelling, postmenopausal women, aged 55 years or older, with vitamin D inadequacy (serum 25(OH)D levels <30 ng/ml, with mean 25(OH)D below 20 ng/ml, namely 16.5 ± 7.5 ng/ml) were randomized to receive three different dosages of calcidiol: 20 μg/day, 40 μg/day, and 125 μg/week for 3 months. The attained level of serum 25(OH)D was selected as primary endpoint to assess efficacy, while other parameters of mineral metabolism, (serum calcium, parathyroid hormone, phosphate, FGF23, urinary calcium, and markers of bone turnover) were assessed as secondary endpoints to establish safety. RESULTS: In all the three groups, serum 25(OH)D values significantly and promptly rose and plateaued above the 30 ng/ml threshold remaining within safety interval after 14 days of treatment, with similar efficacy for the similar daily and weekly dose regimens. The different dosages were also equally effective in controlling secondary hyperparathyroidism. No significant changes in calcium and phosphate metabolism and in bone turnover markers were observed for any of the treatments, confirming the safety of this compound. CONCLUSIONS: The results of this study demonstrate the short- and mid-term efficacy and safety on core parameters of mineral metabolism of different daily or weekly dosages of calcidiol when used to treat vitamin D inadequacy or deficiency in postmenopausal women. Further studies are needed to assess falls as primary outcome of calcidiol supplementation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Minisola S, Cianferotti L, Biondi P, et al. Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. Osteoporos Int. 2017. PMID: 28815282. doi:10.1007/s00198-017-4180-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。